Advertisement

18F-FDG PET/MRI for therapy response assessment in sarcoma: comparison of PET and MR imaging results

      Abstract

      Background

      18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) has proven to be of substantial benefit in imaging of sarcoma patients. We therefore investigated the feasibility and benefit of combined PET/magnetic resonance imaging (MRI).

      Methods

      Twelve patients with sarcoma who underwent FDG PET/MRI for staging and response assessment after chemotherapy were included.

      Results

      Based on contrast-enhanced MRI and application of Choi criteria, therapy response was classified as stable disease in 6/12 patients (50%) and as partial remission in 6/12 patients (50%).

      Conclusion

      In sarcoma patients, response assessment using Choi criteria based on contrast-enhanced MRI in comparison to FDG PET imaging only demonstrates slight correlation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rakheja R
        • Makis W
        • Tulbah R
        • Skamene S
        • Holcroft C
        • Nahal A
        • et al.
        Necrosis on FDG PET/CT correlates with prognosis and mortality in sarcomas.
        Am J Roentgenol. 2013; 201: 170-177https://doi.org/10.2214/AJR.12.9795
        • Brown FM
        • Fletcher CDM
        Problems in grading soft tissue sarcomas.
        Am J Clin Pathol (Pathol Patterns Reviews). 2000; 114: S82-S89
        • Stacchiotti S
        • Collini P
        • Messina A
        • Morosi C
        • Barisella M
        • Bertulli R
        • et al.
        High-grade soft-tissue sarcomas: tumor response assessment—pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.
        Radiology. 2009; 251: 447-456https://doi.org/10.1148/radiol.2512081403
        • Benz MR
        • Czernin J
        • Allen-Auerbach MS
        • Tap WD
        • Dry SM
        • Elashoff D
        • et al.
        FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
        Clin Cancer Res. 2009; 15: 2856-2863https://doi.org/10.1158/1078-0432.CCR-08-2537
        • Eilber FC
        • Rosen G
        • Eckardt J
        • Forscher C
        • Nelson SD
        • Selch M
        • et al.
        Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
        J Clin Oncol. 2001; 19: 3203-3209
        • Evilevitch V
        • Weber WA
        • Tap WD
        • Allen-Auerbach M
        • Chow K
        • Nelson SD
        • et al.
        Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.
        Clin Cancer Res. 2008; 14: 715-720https://doi.org/10.1158/1078-0432.CCR-07-1762
        • Herrmann K
        • Benz MR
        • Czernin J
        • Allen-Auerbach MS
        • Tap WD
        • Dry SM
        • et al.
        18F-FDG-PET/CT imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.
        Clin Cancer Res. 2012; 18: 2024-2031https://doi.org/10.1158/1078-0432.CCR-11-2139
        • Schwenzer NF
        • Schraml C
        • Müller M
        • Brendle C
        • Sauter A
        • Spengler W
        • et al.
        Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging—pilot study.
        Radiology. 2012; 264: 551-558https://doi.org/10.1148/radiol.12111942
        • Platzek I
        • Beuthien-Baumann B
        • Langner J
        • Popp M
        • Schramm G
        • Ordemann R
        • et al.
        PET/MR for therapy response evaluation in malignant lymphoma: initial experience.
        MAGMA. 2013; 26: 49-55https://doi.org/10.1007/s10334-012-0342-7
        • Gaertner FC
        • Beer AJ
        • Souvatzoglou M
        • Eiber M
        • Fürst S
        • Ziegler SI
        • et al.
        Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
        Invest Radiol. 2013; 48: 263-272https://doi.org/10.1097/RLI.0b013e31828234d0
        • Partovi S
        • Kohan AA
        • Zipp L
        • Faulhaber P
        • Kosmas C
        • Ros PR
        • et al.
        Hybrid PET/MR imaging in two sarcoma patients—clinical benefits and implications for future trials.
        Int J Clin Exp Med. 2014; 7: 640-648
        • Schuler MK
        • Richter S
        • Beuthien-Baumann B
        • Platzek I
        • Kotzerke J
        • van den Hoff J
        • et al.
        PET/MRI imaging in high-risk sarcoma: first findings and solving clinical problems.
        Case Rep Oncol Med. 2013; 2013: 793927https://doi.org/10.1155/2013/793927
        • Buchbender C
        • Heusner TA
        • Lauenstein TC
        • Bockisch A
        • Antoch G
        Oncologic PET/MRI, Part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma.
        J Nucl Med. 2012; https://doi.org/10.2967/jnumed.112.109306
        • Forni C
        • Minuzzo M
        • Virdis E
        • Tamborini E
        • Simone M
        • Tavecchio M
        • et al.
        Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
        Mol Cancer Ther. 2009; 8: 449-457https://doi.org/10.1158/1535-7163.MCT-08-0848
        • Grosso F
        • Jones RL
        • Demetri GD
        • Judson IR
        • Blay J-Y
        • Le Cesne A
        • et al.
        Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
        Lancet Oncol. 2007; 8: 595-602https://doi.org/10.1016/S1470-2045(07)70175-4
        • Gronchi A
        • Bui BN
        • Bonvalot S
        • Pilotti S
        • Ferrari S
        • Hohenberger P
        • et al.
        Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.
        Ann Oncol. 2012; 23: 771-776https://doi.org/10.1093/annonc/mdr265
        • Horger M
        • Weisel K
        • Horger W
        • Mroue A
        • Fenchel M
        • Lichy M
        Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results.
        AJR Am J Roentgenol. 2011; 196: W790-W795https://doi.org/10.2214/AJR.10.5979
        • Horger M
        • Claussen C
        • Kramer U
        • Fenchel M
        • Lichy M
        • Kaufmann S
        Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity—a preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging.
        Eur J Radiol. 2014; 83: 1655-1664https://doi.org/10.1016/j.ejrad.2014.05.027
        • Stacchiotti S
        • Verderio P
        • Messina A
        • Morosi C
        • Collini P
        • Llombart-Bosch A
        • et al.
        Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.
        Cancer. 2012; https://doi.org/10.1002/cncr.27624
        • Schuetze SM
        • Baker LH
        • Benjamin RS
        • Canetta R
        Selection of response criteria for clinical trials of sarcoma treatment.
        Oncologist. 2008; 13: 32-40https://doi.org/10.1634/theoncologist.13-S2-32
        • Kelloff GJ
        • Hoffman JM
        • Johnson B
        • Scher HI
        • Siegel BA
        • Cheng EY
        • et al.
        Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
        Clin Cancer Res. 2005; 11: 2785-2808https://doi.org/10.1158/1078-0432.CCR-04-2626
        • Schuetze SM
        • Rubin BP
        • Vernon C
        • Hawkins DS
        • Bruckner JD
        • Conrad EU
        • et al.
        Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
        Cancer. 2005; 103: 339-348https://doi.org/10.1002/cncr.20769
        • Schuetze SM
        Utility of positron emission tomography in sarcomas.
        Curr Opin Oncol. 2006; 18: 369-373https://doi.org/10.1097/01.cco.0000228744.49294.12
        • Van den Hoff J
        • Lougovski A
        • Schramm G
        • Maus J
        • Oehme L
        • Petr J
        • et al.
        Correction of scan time dependence of standard uptake values in oncological PET.
        EJNMMI Res. 2014; 4: 18https://doi.org/10.1186/2191-219X-4-18
        • Choi H
        • Charnsangavej C
        • Faria SC
        • Macapinlac HA
        • Burgess MA
        • Patel SR
        • et al.
        Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
        J Clin Oncol. 2007; 25: 1753-1759https://doi.org/10.1200/JCO.2006.07.3049
        • Torigian DA
        • Lopez RF
        • Alapati S
        • Bodapati G
        • Hofheinz F
        • van den Hoff J
        • et al.
        Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT.
        Hell J Nucl Med. 2011; 14: 8-14
        • Hofheinz F
        • Pötzsch C
        • Oehme L
        • Beuthien-Baumann B
        • Steinbach J
        • Kotzerke J
        • et al.
        Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets.
        Nuklearmedizin. 2012; 51: 9-16https://doi.org/10.3413/Nukmed-0419-11-07
        • Young H
        • Baum R
        • Cremerius U
        • Herholz K
        • Hoekstra O
        • Lammertsma AA
        • et al.
        Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
        Eur J Cancer. 1999; 35: 1773-1782
        • Landis JR
        • Koch GG
        An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers.
        Biometrics. 1977; 33: 363-374
        • Loft A
        • Jensen KE
        • Löfgren J
        • Daugaard S
        • Petersen MM
        PET/MRI for preoperative planning in patients with soft tissue sarcoma: a technical report of two patients.
        Case Rep Med. 2013; 2013: 791078https://doi.org/10.1155/2013/791078
        • Völker T
        • Denecke T
        • Steffen I
        • Misch D
        • Schönberger S
        • Plotkin M
        • et al.
        Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
        J Clin Oncol. 2007; 25: 5435-5441https://doi.org/10.1200/JCO.2007.12.2473
        • Denecke T
        • Hundsdörfer P
        • Misch D
        • Steffen IG
        • Schönberger S
        • Furth C
        • et al.
        Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters.
        Eur J Nucl Med Mol Imaging. 2010; 37: 1842-1853https://doi.org/10.1007/s00259-010-1484-3
        • Pearce MS
        • Salotti JA
        • Little MP
        • McHugh K
        • Lee C
        • Kim KP
        • et al.
        Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study.
        Lancet. 2012; 380: 499-505https://doi.org/10.1016/S0140-6736(12)60815-0
        • Miki Y
        • Ngan S
        • Clark JCM
        • Akiyama T
        • Choong PFM
        The significance of size change of soft tissue sarcoma during preoperative radiotherapy.
        Eur J Surg Oncol. 2010; 36: 678-683https://doi.org/10.1016/j.ejso.2010.05.021